Poolbeg Pharma PLC (POLB.L)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Cathal Martin Friel | Executive Chairman of The Board | 138k | -- | 1964 |
| Dr. Jeremy Skillington Ph.D. | CEO & Director | 310k | -- | 1971 |
| Mr. Ian O'Connell | CFO & Director | 220k | -- | 1987 |
| Carol Dalton | Vice President of Investor Relations & Public Relations | -- | -- | -- |
| Mr. John McEvoy | Senior Vice President & Chief Legal Officer | -- | -- | -- |
| Mr. David James Allmond | Chief Business Officer | -- | -- | 1970 |
| Mr. Salim Gulamabbas Hamir F.C.A. | Company Secretary | -- | -- | -- |
| Mr. Ross Crockett | Group Financial Controller | -- | -- | -- |
Poolbeg Pharma PLC
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 12
Description
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Corporate Governance
Recent Events
Recent Events Information Not Available